Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Statins, widely used for cardiovascular risk reduction, may inhibit coenzyme Q(10) (CoQ(10)) synthesis, potentially impacting vascular health.
• Endothelial dysfunction is a hallmark of cardiovascular disease, particularly in patients with type 2 diabetes mellitus.

Purpose of the Study:

• To investigate the effect of oral coenzyme Q(10) (CoQ(10)) supplementation on endothelial dysfunction in type 2 diabetic patients undergoing statin therapy.
• To determine if CoQ(10) supplementation can mitigate the potential negative vascular effects associated with statin use.

Main Methods:

• A double-blind, placebo-controlled crossover study involving 23 type 2 diabetic patients with suboptimal endothelial function (brachial artery flow-mediated dilatation [FMD] <5.5%) on statin treatment.
• Participants received either oral CoQ(10) (200 mg/day) or placebo for 12 weeks, followed by a crossover period. Brachial artery FMD and nitrate-mediated dilatation (NMD) were measured using ultrasonography.
• Systemic oxidative stress was assessed by measuring plasma F(2)-isoprostane and 24-h urinary 20-hydroxyeicosatetraenoic acid (HETE) levels.

Main Results:

• Coenzyme Q(10) (CoQ(10)) supplementation significantly improved brachial artery flow-mediated dilatation (FMD) by 1.0% (P = 0.04) compared to placebo.
• No significant changes were observed in nitrate-mediated dilatation (NMD), plasma F(2)-isoprostane, or urinary 20-HETE levels following CoQ(10) supplementation.
• The findings suggest a specific improvement in endothelial function rather than a systemic reduction in oxidative stress markers.

Conclusions:

• Oral coenzyme Q(10) (CoQ(10)) supplementation effectively improved endothelial dysfunction in type 2 diabetic patients receiving statin therapy.
• The beneficial effect may be attributed to a localized action on vascular mechanisms, potentially related to oxidative stress within the vasculature.
• CoQ(10) supplementation represents a potential therapeutic strategy to address statin-associated endothelial dysfunction in this patient population.